Please login to the form below

Not currently logged in
Email:
Password:

Sophia Genetics appoints CFO

Valentin Matillon joins firm from the Hobart Group

Data-driven medicine firm Sophia Genetics has appointed its new chief financial officer in the form of Valentin Matillon.

He brings over two decades worth of experience in senior financial management positions to the group, holding roles in technology organisations including SITA, Hewlett-Packard and Electronic Arts.

He said: “Our ground breaking technology and approach are revolutionising the healthcare field, improving the prognosis of patients worldwide and I look forward to supporting the company through its journey of growth and development.”

Matillon joins Sophia Genetics from the Hobart Group, where he served as senior director of finance.

His new role will see him take responsibility for the company’s finance and accounting functions.

Jurgi Camblong, chief executive officer and co-founder of Sophia Genetics, said: “Matillon’s track record in transforming finance functions and supporting new acquisitions, along with his pragmatic and results-driven approach, make him a natural fit for the fast-paced culture of Sophia Genetics.”

19th January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics